We scan new podcasts and send you the top 5 insights daily.
Edward van Vaesel says the US team he met had worked on ibrutinib at Pharmacyclics and knew the BTK investigator network. Without that experience and access, funding Asserta from the Netherlands would have been far harder. He says the company might not have secured sufficient funding or reached key investigators if it had stayed Dutch-based.
Edward van Vaesel says Europe generates nearly as much science and IP as the US, but lacks the capital markets, risk appetite and trial infrastructure to translate it. He notes European companies often run first trials in the US or Australia because patient access is faster and cheaper.
In a tough funding market for companies without clinical data, Ikarovec's CEO notes that investors heavily weigh the team's credibility. The combination of his own experience with FDA approvals, a seasoned CSO, and a board with multiple billion-dollar exits is a key factor that resonates with investors.
When a competitor (Beijing) presented similar positive data for its BTK degrader, the CEO of Neurix viewed it as a positive reinforcement for the entire drug class. In a novel field, parallel success from independent companies de-risks the underlying biological mechanism for investors, partners, and clinicians.
Leiden Labs, a Dutch company founded by industry veterans, failed to raise capital from local investors but secured $30 million from US VCs, including Google Ventures, within a week. This illustrates the faster pace and higher risk appetite of the US venture ecosystem for European biotech.
Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.
To prepare for its internally discovered drugs, Eikon Therapeutics first in-licensed external programs. This allowed their newly-formed clinical team, led by a Merck veteran, to build cohesion and processes on existing assets, avoiding the risk of testing their teamwork for the first time on novel, internally-developed molecules.
Complement Therapeutics intentionally built a presence across the UK, Germany, and the US to optimize talent acquisition. This cross-geographical structure allows them to hire the best experts in a specialized field like gene therapy, irrespective of their location, without being constrained by a single talent pool or dealing with complex relocations.
Edward van Vaesel says Merck/MSD was reorganizing and firing local staff, which made it willing to discuss out-licensing a shelved compound. Asserta secured rights to a preclinical asset that the big pharma had overlooked. That access was the starting point for the company and a very useful one.
Assertifarma's pivotal US team, with crucial experience on a competitor's drug, was found by chance. BGV's founder was pitched by them at a conference but flipped the script and recruited them for his own project, proving the power of opportunistic networking and recognizing expertise on the fly.
Europe's strong science is often held back by a lack of serial entrepreneurs, difficulty in raising follow-on funding, and a localized competitive view. Curie.Bio’s model directly counters these issues by providing an experienced drug-making team, a clear funding path, and an embedded global market perspective.